[go: up one dir, main page]

NO973679L - Eukaryotic initiation factor 5A (eIF-5A) mutants - Google Patents

Eukaryotic initiation factor 5A (eIF-5A) mutants

Info

Publication number
NO973679L
NO973679L NO973679A NO973679A NO973679L NO 973679 L NO973679 L NO 973679L NO 973679 A NO973679 A NO 973679A NO 973679 A NO973679 A NO 973679A NO 973679 L NO973679 L NO 973679L
Authority
NO
Norway
Prior art keywords
eif
mutants
initiation factor
eukaryotic initiation
rev function
Prior art date
Application number
NO973679A
Other languages
Norwegian (no)
Other versions
NO973679D0 (en
Inventor
Joachim Hauber
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9502771.0A external-priority patent/GB9502771D0/en
Priority claimed from GBGB9513505.9A external-priority patent/GB9513505D0/en
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of NO973679D0 publication Critical patent/NO973679D0/en
Publication of NO973679L publication Critical patent/NO973679L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

eIF-5A mutante proteiner som normalt er fri for betydelig eIF-5A akt:ivicet og som inhiberer Rev funksjon og således besitter en inhiberende fenotype med hensyn til Rev funksjon, og gener eller DNA eller cDNA sekvenser som koder derfor.eIF-5A mutant proteins that are normally free of significant eIF-5A act: ivicet and which inhibit Rev function and thus possess an inhibitory phenotype with respect to Rev function, and genes or DNA or cDNA sequences encoding them.

NO973679A 1995-02-13 1997-08-11 Eukaryotic initiation factor 5A (eIF-5A) mutants NO973679L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9502771.0A GB9502771D0 (en) 1995-02-13 1995-02-13 Organic compounds
GBGB9513505.9A GB9513505D0 (en) 1995-07-03 1995-07-03 Organic compounds
PCT/EP1996/000585 WO1996025492A1 (en) 1995-02-13 1996-02-12 EUKARYOTIC INITIATION FACTOR 5A (eIF-5A) MUTANTS

Publications (2)

Publication Number Publication Date
NO973679D0 NO973679D0 (en) 1997-08-11
NO973679L true NO973679L (en) 1997-10-13

Family

ID=26306494

Family Applications (1)

Application Number Title Priority Date Filing Date
NO973679A NO973679L (en) 1995-02-13 1997-08-11 Eukaryotic initiation factor 5A (eIF-5A) mutants

Country Status (15)

Country Link
EP (1) EP0811060A1 (en)
JP (1) JPH10509327A (en)
KR (1) KR19980702160A (en)
CN (1) CN1173897A (en)
AU (1) AU4665196A (en)
BR (1) BR9606951A (en)
CA (1) CA2210538A1 (en)
CZ (1) CZ255397A3 (en)
FI (1) FI972763A (en)
HU (1) HUP9801681A3 (en)
IL (1) IL117113A0 (en)
NO (1) NO973679L (en)
PL (1) PL321239A1 (en)
SK (1) SK109997A3 (en)
WO (1) WO1996025492A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448040B1 (en) * 1997-06-20 2002-09-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitor of cellular proliferation
US7217517B2 (en) * 2001-07-23 2007-05-15 Senesco Technologies, Inc. Nucleic acids, polypeptides, and methods for modulating apoptosis
US6867237B1 (en) * 2001-07-23 2005-03-15 Senesco Technologies, Inc. DNA encoding apoptosis-induced eucaryotic initiation factor-5A and deoxyhypusine synthase and a method for controlling apoptosis in animals and humans
US7968523B2 (en) * 2001-07-23 2011-06-28 Senesco Technologies, Inc. Method for inducing apoptosis using apoptosis-specific EIF5-A
US7166467B2 (en) * 2001-07-23 2007-01-23 Senesco Technologies, Inc. Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis
US7381708B2 (en) 2001-07-23 2008-06-03 Sensco Technologies, Inc. Suppression of eIF5A1 expression by the use of antisense oligonucleotides for the prevention of retinal cell death in the glaucomatous eye
TW200427695A (en) 2003-03-05 2004-12-16 Senesco Technologies Inc Use of antisense oligonucleotides or sirna to suppress expression of eif-5a1
AU2004258070B2 (en) * 2003-06-06 2008-12-11 Senesco Technologies, Inc. Inhibition of apoptosis-specific elF-5A ("elF-5A1") with antisense oligonucleotides and siRNAs as anti-inflammatory therapeutics
US8703929B2 (en) 2008-03-07 2014-04-22 Senesco Technologies, Inc. Compositions comprising siRNA and plasmids
US8445638B2 (en) 2008-09-03 2013-05-21 Senesco Technologies, Inc. Use of a truncated eIF-5A1 polynucleotide to induce apoptosis in cancer cells

Also Published As

Publication number Publication date
FI972763A0 (en) 1997-06-26
BR9606951A (en) 1997-10-28
KR19980702160A (en) 1998-07-15
JPH10509327A (en) 1998-09-14
CZ255397A3 (en) 1998-02-18
HUP9801681A3 (en) 2000-10-30
IL117113A0 (en) 1996-06-18
HUP9801681A2 (en) 1998-10-28
AU4665196A (en) 1996-09-04
MX9705757A (en) 1998-07-31
NO973679D0 (en) 1997-08-11
CA2210538A1 (en) 1996-08-22
EP0811060A1 (en) 1997-12-10
WO1996025492A1 (en) 1996-08-22
PL321239A1 (en) 1997-11-24
CN1173897A (en) 1998-02-18
FI972763A (en) 1997-10-10
SK109997A3 (en) 1998-04-08

Similar Documents

Publication Publication Date Title
Gray et al. PA28 activator protein forms regulatory caps on proteasome stacked rings
MD430C2 (en) Method for human leucocytar interferone preparation
NO973679L (en) Eukaryotic initiation factor 5A (eIF-5A) mutants
ATE440863T1 (en) CHEMOKINE PEPTIDES, VARIANTS, DERIVATIVES AND ANALOGUES. THEIR USE IN METHOD FOR INHIBITING OR INCREASE AN INFLAMMATORY RESPONSE
HUP0103993A2 (en) Ecdysone receptors and methods for their use
SG141233A1 (en) Control of gene expression
WO1997035990A3 (en) Histone deacetylases, and uses related thereto
NO931955L (en) RECEPTORS FOR LEUKEMI INHIBITING FACTOR
AU7443901A (en) Genetically-engineered mhc molecules
DE69434614D1 (en) CDN APOPTOSIS MODULATING PROTEINS, THE ENCODING DNA, AND METHOD FOR THEIR USE
Exner et al. Posttranslational modification of Gαo1 generates Gαo3, an abundant G protein in brain
DK0719328T3 (en) Genet GRB 3-3, variants thereof and their use
DK0662134T3 (en) Polypeptides involved in the biosynthesis of Streptogramin, nucleotide sequences encoding these polypeptides, and their use
EP0676469A3 (en) Transcription Factor APRF
HUP0300297A2 (en) Isolation and characterization of the csa operon (etec-cs4 pili) and methods of using same
DE60238333D1 (en) ANTIBIOTIC-BASED GENREGULATION SYSTEM
DK0643719T3 (en) Nucleic acid sequences encoding or complementary to nucleic acid sequences encoding interleukin 9 receptor
WO2000012741A3 (en) Inducible expression system
AU669149B2 (en) Expression signal-peptide-free staphylokinases
DE69526087D1 (en) OR-1, A WAIS RECEPTOR FROM THE NUCLEAR RECEPTOR FAMILY
ATE362768T1 (en) PRB2/P130 PEPTIDE INHIBITORS OF CDK2 KINASE ACTIVITY
DK0616642T3 (en) Novel thrombin inhibitory proteins from terrestrial blood vessels
WO2002033104A3 (en) Antibiotic-based gene regulation system
Shi et al. GM‐CSF induces the tyrosine phosphorylation of three isoforms of shc and its association with GRB2 in TF‐1 cell
AU7291696A (en) Retroviral vectors carrying senescent cell derived inhibitors 1 (sdi-1) or antisense sdi-1 nucleotide sequences